Folgen
Daniel G. Greene
Titel
Zitiert von
Zitiert von
Jahr
Biophysical Techniques for Characterizing the Higher Order Structure and Interactions of Monoclonal Antibodies
State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal …, 2015
422015
A critical examination of the decoupling approximation for small-angle scattering from hard ellipsoids of revolution
DG Greene, DV Ferraro, AM Lenhoff, NJ Wagner
Journal of Applied Crystallography 49 (5), 1734-1739, 2016
262016
Caffeine as a viscosity reducer for highly concentrated monoclonal antibody solutions
Y Zeng, T Tran, P Wuthrich, S Naik, J Davagnino, DG Greene, ...
Journal of Pharmaceutical Sciences 110 (11), 3594-3604, 2021
192021
Impact of polymer geometry on the interactions of protein-PEG conjugates
J Zarzar, W Shatz, N Peer, R Taing, B McGarry, Y Liu, DG Greene, ...
Biophysical Chemistry 236, 22-30, 2018
182018
Local crystalline structure in an amorphous protein dense phase
DG Greene, S Modla, NJ Wagner, SI Sandler, AM Lenhoff
Biophysical journal 109 (8), 1716-1723, 2015
162015
The role of defects on the assembly and stability of DNA nanostructures
DG Greene, JW Keum, H Bermudez
small 8 (9), 1320-1325, 2012
142012
Structural characterization and developability assessment of sustained release hydrogels for rapid implementation during preclinical studies
P Agarwal, DG Greene, S Sherman, K Wendl, L Vega, H Park, ...
European Journal of Pharmaceutical Sciences 158, 105689, 2021
92021
Stabilizing excipients for therapeutic protein formulations
DS Soane, RP Mahoney, P Wuthrich, DG Greene
US Patent 10,279,048, 2019
82019
Excipient compounds for biopolymer formulations
DS Soane, P Wuthrich, RC Portilla, RP Mahoney, M Moody, DG Greene
US Patent 10,478,498, 2019
62019
Mechanisms of precipitate formation during the purification of an Fc‐fusion protein
DG Greene, SJ Traylor, J Guo, LH Choe, S Modla, X Xu, N Singh, LL Lock, ...
Biotechnology and bioengineering 115 (10), 2489-2503, 2018
62018
Comicellization of binary PEO–PPO–PEO triblock copolymer mixtures in ethylammonium nitrate
R Xie, CR López-Barrón, DG Greene, NJ Wagner
Macromolecules 51 (4), 1453-1461, 2018
62018
Stabilizing excipients for therapeutic protein formulations
DS Soane, RP Mahoney, P Wuthrich, DG Greene
US Patent App. 16/789,803, 2020
52020
Stabilizing excipients for therapeutic protein formulations
DS Soane, RP Mahoney, P Wuthrich, DG Greene
US Patent 10,016,513, 2018
52018
Excipient compounds for protein processing
DS Soane, P Wuthrich, RP Mahoney, M Moody, DG Greene, NL Schauer
US Patent 11,357,857, 2022
42022
Excipient compounds for biopolymer formulations
DS Soane, P Wuthrich, RC Portilla, RP Mahoney, M Moody, DG Greene
US Patent App. 16/659,046, 2020
42020
The formation and structure of precipitated protein phases
DG Greene
University of Delaware, 2016
42016
Stabilizing excipients for therapeutic protein formulations
DS Soane, RP Mahoney, P Wuthrich, DG Greene
US Patent 10,610,600, 2020
32020
Nanocrystalline protein domains via salting-out
DG Greene, S Modla, SI Sandler, NJ Wagner, AM Lenhoff
Acta Crystallographica Section F: Structural Biology Communications 77 (11 …, 2021
12021
Excipient compounds for protein formulations
DS Soane, P Wuthrich, RP Mahoney, S Naik, T Tran, RC Portilla, ...
US Patent App. 17/011,014, 2021
12021
Stabilizing excipients for therapeutic protein formulations
DS Soane, RP Mahoney, P Wuthrich, DG Greene
12020
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20